TradingView’s own chart and price feed. The page’s numbers are end-of-day closes.
Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via Databento
Market cap$400M
Enterprise value$395.3M
Revenue$190,000 −19.1%
True FCF (ex-SBC)$-67.1M +10.3%
Rule of 40-32683.8%
ROIC-124.5%
True FCF Yield-16.8%
EPS, diluted$-0.80 +7.0%
Modern Valuation (EOD)
Market Cap$400M
Enterprise Value$395.3M
EV / True FCF—
EV / FCF—
EV / Gross Profit—
EV / EBIT—
EV / Sales2080.30
P / E (GAAP)—
P / FCF—
P / Oper. CF—
P / Book5.95
Owner & Cash Yields
True FCF Yield-16.8%
FCF Yield-15.5%
Owner Earn. Yield-19.6%
Earnings Yield-18.5%
Shareholder Yield—
Buyback Yield—
Dividend Yield—
Dividend / sh—
Payout Ratio—
FCF / sh$-24.35
EPS (diluted)$-0.80
Compounder & Returns
Rule of 40-32683.8%
ROIC-124.5%
Cash ROIC (CROIC)-99.5%
GP / Assets—
ROE-110.2%
ROA-79.7%
Gross Margin—
Oper. Margin-40856.3%
Net Margin-39009.5%
FCF Margin-32664.7%
True FCF Margin-35294.7%
Quality & Dilution
Cash Conversion—
Accrual Ratio−13.0%
SBC % of FCF—
SBC % of Rev2630.0%
Reinvest. Rate—
Sales Growth Y/Y−19.1%
Sales 3Y CAGR−73.7%
EPS Growth Y/Y+7.0%
FCF Growth Y/Y+10.3%
FCF 3Y CAGR—
Share Change Y/Y+25.2%
Balance Sheet & Scale
Revenue (FY)$190,000
Gross Profit (FY)—
Oper. Income (FY)$-77.6M
GAAP Net Income$-74.1M
True FCF (ex-SBC)$-67.1M
Cash & Equiv$10.7M
Total Debt$5.8M
Net Cash (Debt)$4.9M
Net Cash % MCap+1.2%
Debt / FCF (yrs)—
Current Ratio5.302.55M sh
Price & Technicals (EOD)
Perf Week−37.43%
Perf Month+2147.06%
Perf Quarter+620.75%
Perf Half Y+679.59%
Perf YTD+353.57%
SMA 20 Dist−22.23%$4.91
SMA 50 Dist+79.27%$2.13
SMA 100 Dist+188.39%$1.32
Window High−49.60%$7.58
Window Low+2980.65%$0.12
RSI (14) · Vol48.41348%v
Income Distribution & Cash Flow ConversionHow every dollar of ATYR revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
Operating Cash Flow (OCF)$-62.0M(-32624.2% of rev)
Less: Capital Expenditures−$77,000(40.5% of rev)
Standard Free Cash Flow (FCF)$-62.1M(-32664.7% margin)
Less: Stock-Based Comp (SBC)−$5.0M
True FCF (Owner Cash ex-SBC)$-67.1M(-35294.7% of rev)
Revenue by fiscal year
$0FY21
$10.4MFY22
$353,000FY23
$235,000FY24
$190,000FY25
Operating leverage — margins
GrossOperatingNet
Unlocked SEC EDGAR Accounting Statements (USD)All 3 statements · Common-size (% of Revenue / Assets) · YoY growth · Tap any core row to explain
Line Item (USD)
FY2021
FY2022
FY2023
FY2024
FY2025
YoY Δ
4Y CAGR
Trend
Income Statement
Revenue ▸
$0
$10.4M
$353,000
$235,000
$190,000
−19.1%
—
Research & Development (R&D)
$23.3M
$42.8M
$42.3M
$54.4M
$60.2M
+10.8%
+26.8%
Total Operating Expenses
$34.0M
$56.8M
$55.3M
$68.1M
$77.8M
+14.2%
+23.0%
Operating Income (EBIT) ▸
$-34.0M
$-46.4M
$-54.9M
$-67.9M
$-77.6M
−14.3%
—
Income Tax Expense
$0
$0
$0
$0
$0
—
—
GAAP Net Income ▸
$-33.8M
$-45.3M
$-50.4M
$-64.0M
$-74.1M
−15.8%
—
Diluted EPS ▸
$-1.77
$-1.60
$-0.94
$-0.86
$-0.80
+7.0%
—
Diluted Shares
19.1M
28.4M
53.6M
74.3M
93.0M
+25.2%
+48.6%
Balance Sheet
Cash & Equivalents
$2.3M
$10.0M
$22.5M
$11.1M
$10.7M
−2.8%
+46.4%
Total Current Assets
$113.6M
$80.9M
$103.0M
$82.0M
$80.2M
−2.1%
−8.3%
Total Assets
$115.5M
$95.8M
$120.7M
$96.8M
$93.0M
−4.0%
−5.3%
Total Current Liabilities
$6.0M
$13.9M
$16.4M
$15.0M
$15.1M
+1.2%
+26.0%
Total Debt (Short + Long Term)
$5.8M
$5.8M
$5.8M
$5.8M
$5.8M
+0.0%
+0.0%
Stockholders' Equity
$109.1M
$71.3M
$90.5M
$69.8M
$67.3M
−3.6%
−11.4%
Net Cash / (Net Debt)
$-3.5M
$4.2M
$16.7M
$5.3M
$4.9M
−5.9%
—
Invested Capital
$112.6M
$67.1M
$73.7M
$64.6M
$62.3M
−3.5%
−13.7%
Cash Flow & Capital Allocation
Operating Cash Flow (OCF) ▸
$-33.1M
$-41.9M
$-33.2M
$-69.1M
$-62.0M
+10.3%
—
Depreciation & Amortization (D&A)
$475,000
$232,000
$592,000
$708,000
$664,000
−6.2%
+8.7%
Stock-Based Compensation (SBC)
$1.6M
$2.2M
$2.6M
$3.0M
$5.0M
+67.2%
+32.6%
Capital Expenditures (CapEx)
$192,000
$1.6M
$4.2M
$65,000
$77,000
+18.5%
−20.4%
Free Cash Flow (FCF) ▸
$-33.3M
$-43.5M
$-37.4M
$-69.2M
$-62.1M
+10.3%
—
True FCF (ex-SBC Owner Cash)
$-34.9M
$-45.7M
$-40.0M
$-72.2M
$-67.1M
+7.1%
—
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.
On the Wire
what ATYR did at the next close after each story
No Wire story has named ATYR yet.
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.
What happened · big days
31 big days in a year, and what we hold on each
A big day is a close more than 9.39% from the one before, three times ATYR’s median day (3.13%). On 0 of the 31, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.
every other trading daya big day, numbered in the list below±9.39%Hover a bar for its day. Click a big day to open it.
Shaded: since our stories began, Jun 10. Tap a bar for its day.
#DayATYRWhat we hold that dayGroup (median of 4) · each
1 Nov 24, 2025+17.02%
Before our storiesgroup −0.0%, did not move with it
1Nov 24, 2025+17.02%
Before our stories
−0.0% did not move with itMRNA +1.8 · BIIB +0.9 · AMGN −1.0 · GILD −1.1
2 Jan 29, 2026+26.16%
Before our storiesgroup +0.5%, did not move with it
2Jan 29, 2026+26.16%
Before our stories
+0.5% did not move with itMRNA +3.4 · BIIB +0.8 · AMGN +0.2 · GILD −0.1
3 Feb 2, 2026+9.90%
Before our storiesgroup +0.1%, did not move with it
3Feb 2, 2026+9.90%
Before our stories
+0.1% did not move with itAMGN +0.8 · GILD +0.7 · BIIB −0.4 · MRNA −3.5
4 Feb 6, 2026+10.89%
Before our storiesgroup +3.3%, did not move with it
4Feb 6, 2026+10.89%
Before our stories
+3.3% did not move with itBIIB +8.5 · AMGN +4.5 · GILD +2.1 · MRNA +0.3
5 Feb 17, 2026+9.97%
Before our storiesgroup +0.7%, did not move with it
5Feb 17, 2026+9.97%
Before our stories
+0.7% did not move with itMRNA +4.0 · AMGN +1.1 · GILD +0.2 · BIIB −0.5
6 Apr 10, 2026+10.99%
Before our storiesgroup −1.7%, did not move with it
6Apr 10, 2026+10.99%
Before our stories
−1.7% did not move with itMRNA −0.6 · AMGN −1.3 · GILD −2.2 · BIIB −2.3
7 May 6, 2026+23.49%
Before our storiesgroup +1.5%, did not move with it
7May 6, 2026+23.49%
Before our stories
+1.5% did not move with itMRNA +4.5 · GILD +2.1 · BIIB +0.8 · AMGN +0.5
8 May 7, 2026−11.37%
Before our storiesgroup −0.6%, did not move with it
8May 7, 2026−11.37%
Before our stories
−0.6% did not move with itGILD −1.6 · AMGN −0.6 · MRNA −0.5 · BIIB +0.4
9 May 12, 2026−44.20%
Resultsgroup +0.9%, did not move with it
9May 12, 2026−44.20%
ResultsFirst close after the May 11 results filing
+0.9% did not move with itBIIB +0.7 · MRNA +0.7 · GILD +1.1 · AMGN +2.0
10 May 13, 2026−25.33%
Before our storiesgroup −0.7%, did not move with it
10May 13, 2026−25.33%
Before our stories
−0.7% did not move with itMRNA −5.3 · GILD −1.4 · AMGN +0.1 · BIIB +2.6
11 May 14, 2026+41.42%
Before our storiesgroup −0.8%, did not move with it
11May 14, 2026+41.42%
Before our stories
−0.8% did not move with itAMGN −0.1 · GILD −0.7 · MRNA −0.8 · BIIB −6.4
12 May 15, 2026−9.98%
Before our storiesgroup −1.9%, did not move with it
12May 15, 2026−9.98%
Before our stories
−1.9% did not move with itAMGN −3.0 · MRNA −2.0 · GILD −1.9 · BIIB +0.8
13 May 20, 2026+9.86%
Before our storiesgroup +0.2%, did not move with it
13May 20, 2026+9.86%
Before our stories
+0.2% did not move with itMRNA +5.3 · AMGN +0.3 · GILD +0.1 · BIIB −1.4
14 May 29, 2026+11.30%
Before our storiesgroup −0.5%, did not move with it
14May 29, 2026+11.30%
Before our stories
−0.5% did not move with itAMGN +0.1 · BIIB −0.2 · MRNA −0.8 · GILD −1.3
15 Jun 23, 2026+14.23%
Nothing on ATYRgroup +0.4%, did not move with it
15Jun 23, 2026+14.23%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
+0.4% did not move with itMRNA +2.8 · AMGN +0.7 · GILD +0.1 · BIIB −1.3
16 Jul 6, 2026+10.36%
Nothing on ATYRgroup −1.7%, did not move with it
16Jul 6, 2026+10.36%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
−1.7% did not move with itMRNA +2.6 · GILD −1.3 · AMGN −2.1 · BIIB −3.5
17 Jul 9, 2026−9.55%
Nothing on ATYRgroup −0.7%, did not move with it
17Jul 9, 2026−9.55%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
−0.7% did not move with itAMGN −1.2 · GILD −0.7 · BIIB −0.7 · MRNA +3.7
18 Jul 15, 2026+9.94%
Nothing on ATYRgroup +1.3%, did not move with it
18Jul 15, 2026+9.94%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
+1.3% did not move with itBIIB +2.8 · GILD +1.3 · MRNA +1.3 · AMGN +0.9
19 Sep 1, 2026−10.38%
Nothing on ATYRgroup +2.2%, did not move with it
19Sep 1, 2026−10.38%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
+2.2% did not move with itBIIB −0.3 · AMGN +1.9 · GILD +2.5 · MRNA +9.9
20 Sep 14, 2026−9.59%
Nothing on ATYRgroup +1.5%, did not move with it
20Sep 14, 2026−9.59%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
+1.5% did not move with itBIIB +0.1 · AMGN +1.1 · GILD +1.9 · MRNA +1.9
21 Sep 24, 2026−10.02%
Nothing on ATYRgroup −0.3%, did not move with it
21Sep 24, 2026−10.02%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
−0.3% did not move with itGILD −1.1 · BIIB −0.5 · AMGN −0.0 · MRNA +7.0
22 Sep 25, 2026−9.66%
Nothing on ATYRgroup +1.5%, did not move with it
22Sep 25, 2026−9.66%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
+1.5% did not move with itBIIB +0.6 · GILD +0.8 · MRNA +2.1 · AMGN +2.1
23 Oct 12, 2026−12.75%
Nothing on ATYRgroup +0.1%, did not move with it
23Oct 12, 2026−12.75%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
+0.1% did not move with itMRNA −5.0 · GILD −0.5 · AMGN +0.7 · BIIB +1.6
24 Oct 27, 2026−19.17%
Nothing on ATYRgroup +0.5%, did not move with it
24Oct 27, 2026−19.17%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
+0.5% did not move with itBIIB +0.2 · GILD +0.3 · AMGN +0.8 · MRNA +4.6
25 Oct 29, 2026+4082.24%
Nothing on ATYRgroup +3.1%, did not move with it
25Oct 29, 2026+4082.24%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
+3.1% did not move with itGILD +4.0 · MRNA +4.0 · BIIB +2.3 · AMGN +2.0
26 Nov 2, 2026+27.33%
Nothing on ATYRgroup −0.3%, did not move with it
26Nov 2, 2026+27.33%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
−0.3% did not move with itAMGN −0.1 · GILD −0.2 · MRNA −0.4 · BIIB −1.8
27 Nov 9, 2026+19.37%
Nothing on ATYRgroup +2.0%, did not move with it
27Nov 9, 2026+19.37%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
+2.0% did not move with itMRNA +5.8 · BIIB +2.6 · GILD +1.5 · AMGN +1.0
28 Nov 11, 2026−10.45%
Nothing on ATYRgroup −0.3%, did not move with it
28Nov 11, 2026−10.45%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
−0.3% did not move with itMRNA −0.8 · GILD −0.7 · BIIB +0.1 · AMGN +0.6
29 Nov 16, 2026−14.17%
Nothing on ATYRgroup −0.7%, did not move with it
29Nov 16, 2026−14.17%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
−0.7% did not move with itMRNA −3.6 · AMGN −0.7 · BIIB −0.7 · GILD −0.3
30 Nov 18, 2026−18.24%
Nothing on ATYRgroup −1.9%, did not move with it
30Nov 18, 2026−18.24%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
−1.9% did not move with itMRNA −4.8 · AMGN −3.1 · GILD −0.8 · BIIB +0.3
31 Nov 19, 2026−9.56%
Nothing on ATYRgroup −1.3%, did not move with it
31Nov 19, 2026−9.56%
Nothing on ATYRNo ATYR story, brief or results filing in our record that day
−1.3% did not move with itBIIB −1.7 · GILD −1.4 · AMGN −1.1 · MRNA +1.3
A story on the same day is not a cause, and a group move is not proof either. Group: the median of AMGN, GILD, MRNA and BIIB that day, the largest companies in ATYR’s SEC industry; “moved with ATYR” means the same direction and at least half the size.
What’s next · results
Before the next report: what the first day after the last four did
Six trading days after each results filing (SEC 8-K, Item 2.02). ATYR reports after the close, so day 1 is the next close. Each time, day 6 ended on the same side as day 1.
Reported Mar 5, 2026
day 1−8.68%day 6−5.80%
Reported May 11, 2026
day 1−44.20%day 6−49.17%
Reported Aug 7, 2026
day 1+3.42%day 6+1.47%
Reported Nov 5, 2026
day 1+5.31%day 6+1.24%
Next report: expected early FebruaryEstimated from the dates of its last four results filings. Not announced. Since the Nov 5 report: −38.81%. Four reports is a small sample.
Each line is ATYR’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.
Same industry
ATYR against four biotech peers, a year at 100
ATYR is up 5.6 times in a year. Moderna is up 8.4 times. Of these four, Biogen (+41.0%), Gilead Sciences (+31.5%) and Amgen (+30.0%) did less. Weekly closes, Nov 21, 2025 = 100, on a log scale so a 8.4-fold rise and a 30.0% rise both read honestly.
End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in ATYR’s SEC industry (Biological Products, (No Diagnostic Substances)) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.